Company Overview of Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of metabolic diseases, cancer, and inflammation. It develops Chemotype Evolution, a technology that enables the rapid identification of drugs through a lead-identification paradigm for the discovery of therapeutics. The company’s therapeutic portfolio pipeline includes GLP-1R and dual GLP-1R/GIPR agonists, which are peptide-small molecule hybrid compounds that activate GLP-1R and GIPR; NEMO/IKK to block pathological NF-kB signaling for therapeutic applications in inflammatory, auto-immune, and oncology diseases; deubiquitinating enzymes that remove ubiquitin from proteins targeted for degradati...
409 Illinois Street
San Francisco, CA 94158
Founded in 2008
Key Executives for Carmot Therapeutics, Inc.
Co-Founder, Chief Executive Officer and Director
Director of Business Development & Operations
Vice President of Business Development
Vice President of Clinical Development
Compensation as of Fiscal Year 2016.
Carmot Therapeutics, Inc. Key Developments
Carmot Therapeutics, Inc. Announces Board Changes
Aug 16 16
Carmot Therapeutics, Inc. announced that Dr. Trombley joins company's Board of Directors as an independent director. She is Vice President, Chief Operating Officer of NGM Biopharmaceuticals. She joined NGM as head of Business Development in 2011. She was most recently from Novartis in Basel, Switzerland, where she was Chief of Staff for the Chief Executive Officer and worked on key corporate initiatives and strategic projects across the company’s healthcare businesses. Previously, she was Associate Director, Business Development at XenoPort, Inc. Elena Viboch, Director of Business Development and Operations, joins Carmot from FLX Bio, where she served as Senior Manager of Corporate Development and Strategy. Prior to FLX Bio, Elena Viboch worked in New Product Planning with Jazz Pharmaceuticals.
Carmot Therapeutics Enters into Collaboration and License Agreement with Genentech, Inc
Jul 7 16
Carmot Therapeutics, Inc. has entered into a drug discovery collaboration and license agreement with Genentech, Inc. As part the agreement, Carmot will apply its lead-identification technology, Chemotype Evolution, to discover novel drug hits. Carmot and Genentech will work together to identify lead candidates, while Genentech will be solely responsible for lead optimization, pre-clinical and clinical development, manufacturing, and commercialization activities. Under the terms of the agreement, Carmot will receive an undisclosed upfront payment and is eligible to receive milestone payments based on achievement of certain predetermined pre-clinical and clinical milestones. In addition, Carmot is eligible to receive royalties on sales of certain products resulting from the license agreement. Financial terms have not been disclosed.
Amgen and Carmot Therapeutics Extend R&D Collaboration
Feb 17 16
Carmot Therapeutics Inc. announced an extension to the R&D partnership struck in 2014 with Amgen Inc. Carmot will continue to utilise its proprietary lead-identification technology, Chemotype Evolution, to advance further molecules discovered as part of the initial collaboration. The clinical development of any newly discovered molecules will be the sole responsibility of Amgen. The agreement gives Carmot the right to research funding, as well as payments tied to pre-clinical and clinical milestones. The company will also be eligible for royalties on commercial sales of products resulting from this collaboration. The financial terms agreed by the parties were not disclosed.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|